Present treatment strategies centre on the management of symptomatic heart failure using guideline-directed heart failure management (GDMT) – a combination of beta-blockers, angiotensin-converting enzyme inhibitors, mineralocorticoid antagonists and SGLT-2 inhibitors (Japp et al., 2016; McDonagh et al., 2021; Heidenreich et al., 2022). Here, SLC5A2 is linked to heart failure.